San Antonio Breast Cancer Symposium | Conference

Pembrolizumab/Trastuzumab Active in HER2-Positive Breast Cancer

December 7th 2017

The combination of pembrolizumab and trastuzumab reached an objective response rate of 15.2% in patients with trastuzumab-resistant, PD-L1–positive, HER2-positive breast cancer.

Alternative Chemotherapy Dosing Strategies Improve Breast Cancer Outcomes

December 6th 2017

Shortening the intervals between chemotherapy cycles or administering the drugs sequentially reduced early-stage breast cancer recurrence and mortality compared with standard dosing techniques.

Sacituzumab Govitecan Highly Effective in Heavily Pretreated mTNBC

December 6th 2017

Treatment with sacituzumab govitecan elicited an objective response rate of 34% in patients with heavily pretreated metastatic triple-negative breast cancer.

Trastuzumab Disappoints in HER2-low Patient Cohort

December 6th 2017

A trial to determine the value of trastuzumab plus standard adjuvant chemotherapy in patients with low levels of HER2 protein has shown no significant efficacy, confounding investigators who launched the trial based on opposing results from 2 earlier studies.

Dual HER2-Blockade Plus AI Shows Promise in HER2+/ER+ Breast Cancer

January 17th 2017

Data from the phase II PERTAIN trial presented late last year at the 2016 San Antonio Breast Cancer Symposium showed that adding an aromatase inhibitor (AI) to pertuzumab and trastuzumab extended progression-free survival by over 3 months versus trastuzumab plus an AI in patients with HER2-positive, HR-positive locally advanced or metastatic breast cancer.

Pegram Sheds Light on Margetuximab in HER2+ Breast Cancer

January 14th 2017

The Fc-modified monoclonal antibody margetuximab in combination with chemotherapy may offer a new treatment option for patients with HER2-positive metastatic breast cancer.

Prophylactic Treatment Reduces Neratinib-Related Toxicity in HER2+ Breast Cancer

January 5th 2017

A prophylactic treatment of loperamide plus budesonide reduced the rate of grade 3 diarrhea associated with neratinib.

Dr. Brufsky on Cobimetinib Plus Paclitaxel in TNBC

January 4th 2017

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses combining cobimetinib and paclitaxel as a first-line treatment in patients with advanced triple-negative breast cancer.

Post-Mastectomy Radiation Associated With Increased Complications for Some Patients

December 22nd 2016

Patients with breast cancer who received radiation therapy after undergoing a mastectomy reported increased complications and lower satisfaction.

Hurvitz Sheds Light on Abemaciclib Activity in HR+/HER2- Breast Cancer

December 20th 2016

The neoadjuvant combination of CDK4/6 inhibitor abemaciclib plus anastrazole may represent a novel therapeutic option for patients with hormone receptor-positive, HER2-negative early breast cancer.

Axillary Lymph Node Dissection Can Be Avoided for Some Patients With Breast Cancer, Study Shows

December 19th 2016

Results of a clinical trial show that an axillary lymph node dissection can be avoided for patients with large, operable tumors in the breast, no clinical signs of cancer in the axillary nodes before being treated with neoadjuvant chemotherapy, and no signs of cancer following a sentinel lymph node biopsy during surgery.

Continuous Low-Dose Ribociclib Both Safe and Active in Advanced Breast Cancer

December 16th 2016

A continuous low-dose of ribociclib demonstrated both preliminary activity and an acceptable safety profile when compared with an intermittent dose of ribociclib when combined with fulvestrant in the treatment of postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Carboplatin Response Rate Not Superior to Docetaxel in BRCA1 Methylated or Silenced TNBC

December 16th 2016

Testing for BRCA1 methylation or mRNA silencing did not predict a better response to carboplatin over docetaxel in patients with advanced triple-negative or BRCA1/2 breast cancer.

Dr. Prat on HER2-Enriched Subtype as Strong Predictor of HER2-Targeted Treatment

December 15th 2016

Aleix Prat, MD, PhD, head of the Department of Medical Oncology, the August Pi i Sunyer Biomedical Research Institute, discusses the results of the open-label PAMELA trial, in which the HER2-enriched subtype predicted pathologic complete response to targeted treatment in patients with HER2-positive, hormone receptor-positive breast cancer.

Dr. Rimawi on Neoadjuvant Estrogen Deprivation Therapy in HER2+ Breast Cancer

December 15th 2016

Mothaffar F. Rimawi, MD, associate professor and medical director at the Lester and Sue Smith Breast Center at the Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, discusses the findings of the NSABP B-52 trial, which explored the addition of neoadjuvant estrogen deprivation therapy to docetaxel and carboplatin plus the HER2 inhibitors trastuzumab (Herceptin) and pertuzumab (Perjeta) as treatment for patients with HER2-positive breast cancer.

Dr. Dieras on Combo of Veliparib and Chemotherapy in BRCA1/2-Mutant Breast Cancer

December 13th 2016

Véronique Diéras, MD, Department of Clinical Research, Institut Curie Paris & Saint Cloud, discusses results of a phase II trial exploring the combination of the PARP inhibitor veliparib with chemotherapy in patients with BRCA1/2-mutant breast cancer.

Brock Schroeder Discusses BCI Findings in ER+ Breast Cancer

December 13th 2016

Brock Schroeder, PhD, senior director, Medical and Scientific Affairs at bioTheranostics, discusses findings regarding the Breast Cancer Index in predicting patients with estrogen receptor (ER)-positive breast cancer at high risk of recurrence.

Dr. Alvarez on Updated Findings With Eribulin in Patients With HER2- Breast Cancer

December 13th 2016

Ricardo H. Alvarez, MD, MSc, director of Cancer Research, breast medical oncologist, Southeastern Regional Medical Center, Cancer Treatment Centers of America, discusses updated findings regarding the mechanism of action with eribulin mesylate (Halaven) and how it impacts patients with HER2-negative breast cancer.

Dr. Nangia on the SCALP Trial for Early-Stage Breast Cancer

December 12th 2016

Julie R. Nangia, MD, assistant professor, Breast Center-Clinic, faculty senator, Baylor College of Medicine, discusses the results of the Scalp Cooling Alopecia Prevention trial (SCALP) for patients with early-stage breast cancer.

Pembrolizumab Shows Durable Responses in Heavily Pretreated TNBC

December 10th 2016

Treatment with pembrolizumab continued to show a consistent durable benefit with an additional year of follow-up for heavily pretreated patients with recurrent PD-L1-positive metastatic triple-negative breast cancer.